• Allergic  states:  Control  of severe or  incapacitating  allergic  conditions intractable to adequate trials  of conventional treatment  in asthma,  atopic  dermatitis, contact dermatitis, drug  hypersensitivity reactions, perennial or seasonal allergic rhinitis,  and serum  sickness.
• Dermatologic diseases:  Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and  severe erythema  multiforme  (Stevens-Johnson  syndrome). 
• Gastrointestinal diseases:  To tide the  patient over  a critical  period of the  disease in  regional enteritis and ulcerative colitis.
• Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic  purpura  in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. 
• Endocrine  disorders: Primary or  secondary  adrenocortical  insufficiency (hydrocortisone or cortisone  is  the drug  of choice; may be used in conjunction with synthetic mineralocorticoid  analogs where  applicable; in  infancy mineralocorticoid supplementation is  of  particular importance), congenital adrenal  hyperplasia,  hypercalcemia associated  with cancer, and nonsuppurative thyroiditis. 
• Neoplastic  diseases: For the palliative  management  of leukemias  and lymphomas. 
• Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when  used concurrently with appropriate anti-tubercular chemotherapy,  idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
• Ophthalmic diseases: Sympathetic  ophthalmia, temporal  arteritis,  uveitis, and  ocular  inflammatory conditions unresponsive to  topical corticosteroids.
• Renal diseases: To induce  a diuresis  or  remission of proteinuria in idiopathic nephrotic  syndrome or that due to lupus erythematosus. 
• Rheumatic disorders: As  adjunctive therapy for  short-term administration  (to tide  the patient over an  acute episode or exacerbation)  in  acute  gouty arthritis, acute  rheumatic carditis, ankylosing  spondylitis, psoriatic arthritis, rheumatoid arthritis, including  juvenile rheumatoid arthritis (selected  cases may require low-dose maintenance therapy). For  the treatment  of dermatomyositis, polymyositis, and  systemic lupus erythematosus. 
• Nervous system:  Acute exacerbations  of multiple  sclerosis,  cerebral  edema  associated  with primary or metastatic  brain tumor, craniotomy, or head injury. 
• Miscellaneous:  Diagnostic testing  of  adrenocortical hyperfunction,  trichinosis with  neurologic  or myocardial involvement, tuberculous  meningitis with subarachnoid  block  or impending block when used with appropriate anti-tubercular chemotherapy. 

Berylliosis	Pulmonary sarcoidosis	Leukemia	Psoriatic Arthritis
Gout	Thyroiditis	Ulcerative Colitis	Dermatitis

For oral administration: Depending on the condition being treated, the starting dosage ranges from 0.75 to 9 mg per day. It is important to remember that dosage requirements are variable and must be customized based on the disease being treated and the patient's response.

For injection:

• First Day: 1 or 2 mL, intramuscularly
• Dexamethasone tablets, 0.75 mg
• Second Day: 4 tablets in two divided doses
• Third Day: 4 tablets in two divided doses
• Fourth Day: 2 tablets in two divided doses
• Fifth Day: 1 tablet
• Sixth Day: 1 tablet
• Seventh Day: No treatment
• Eighth Day: Follow-up visit

Dexamethasone can cause the following side effects-

• Congestive heart failure in susceptible patients
• Hypertension
• Edema
• Hypokalemia
• Hypokalemic alkalosis
• Muscle weakness
• Loss of muscle mass
• Steroid myopathy
• Osteoporosis
• Peptic ulcer with possible perforation and hemorrhage
• Pancreatitis
• Abdominal distention
• Ulcerative esophagitis
• Increased sweating
• Development of Cushingoid state
• Suppression of growth in children
• Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness
• Menstrual irregularities
• Decreased carbohydrate tolerance
• Manifestations of latent diabetes mellitus

Hypertension (Hight Blood Pressure)	Edema	Hypokalemia (Low Potassium)
Pancreatitis	Osteoporosis (Brittle Bone)	Excessive Sweating (Hyperhidrosis)

• Some indications of infection may be hidden by corticosteroids, and new infections may develop as a result of their use. Infections with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic infections, may be linked to the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function, in any part of the body.
• The risk of drug-induced secondary adrenocortical insufficiency can be reduced by gradually lowering the dosage. This form of relative insufficiency can last for months after you stop taking hormone therapy, therefore if you have a stressful circumstance during that time, hormone therapy should be resumed.
• Corticosteroids have a stronger effect on hypothyroidism patients and those with cirrhosis.
• Because of the risk of corneal perforation, corticosteroids should be taken with caution in individuals with ocular herpes simplex.
• To regulate the condition being treated, the lowest possible amount of corticosteroid should be utilized, and when dosage reduction is possible, it should be done gradually.
• In individuals with systemic sclerosis, caution is advised since corticosteroids, particularly methylprednisolone, have been linked to an increased risk of scleroderma renal crisis.
• If there is a risk of impending perforation, abscess, or other pyogenic infection, steroids should be used with caution in nonspecific ulcerative colitis; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency;
• Infants and children receiving long-term corticosteroid medication should have their growth and development monitored closely.